ArticleFrontiers in pediatrics2026
Machine learning based on radiomics for discriminating sellar region langerhans cell histiocytosis from germ cell tumors.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiating sellar region germ cell tumors (GCTs) from Langerhans cell histiocytosis (LCH) is challenging due to highly similar MRI features, especially in tumor marker-negative patients. In this study, we aimed to develop and validate a radiomics model to distinguish tumor marker-negative sellar GCTs from LCH. Methods: This retrospective study enrolled a total of 93 patients diagnosed pathologically or by therapeutic diagnosis at our single institution between April 2012 and April 2024, including 40 cases of LCH and 53 cases of GCTs. Radiomics features extracted from multiparametric MRI, including T1-weighted imaging (T1WI) and T2-weighted imaging (T2WI). We manually segmented the regions of interests (ROIs) of tumors. Feature selection was subsequently performed using LASSO regression with five-fold cross-validation. We have chosen three machine learning classifiers-Support Vector Machine (SVM), Random Forest (RF), and Logistic Regression (LR) to construct models based on the 7 features which were retained. Additionally, by integrating clinically significant features and imaging semantic features, classification models based on radiomics features, imaging semantic features, and clinical features were developed separately. There are 7 models in total. Furthermore, combined prediction models were constructed based on different fusion feature sets, respectively. The performance of the diagnostic model was evaluated using the receiver operating characteristic (ROC) curve. The mean area under the curve (AUC), sensitivity, specificity, accuracy, and F1-score were calculated for both the development set and the test set. Differences in AUC between models were assessed using DeLong's test, and the resulting Results: The best diagnostic performance was achieved by the combined model of radiomics with clinical features and imaging semantic features using the RF classifier, with an AUC value of 0.81. A statistically significant difference ( Conclusion: Radiomics-based machine learning is a promising, non-invasive approach to distinguish tumor marker-negative sellar GCTs from LCH, which has good predictive performance and may help with treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.